Literature DB >> 24699705

Antiviral strategies against influenza virus: towards new therapeutic approaches.

Arianna Loregian1, Beatrice Mercorelli, Giulio Nannetti, Chiara Compagnin, Giorgio Palù.   

Abstract

Influenza viruses are major human pathogens responsible for respiratory diseases affecting millions of people worldwide and characterized by high morbidity and significant mortality. Influenza infections can be controlled by vaccination and antiviral drugs. However, vaccines need annual updating and give limited protection. Only two classes of drugs are currently approved for the treatment of influenza: M2 ion channel blockers and neuraminidase inhibitors. However, they are often associated with limited efficacy and adverse side effects. In addition, the currently available drugs suffer from rapid and extensive emergence of drug resistance. All this highlights the urgent need for developing new antiviral strategies with novel mechanisms of action and with reduced drug resistance potential. Several new classes of antiviral agents targeting viral replication mechanisms or cellular proteins/processes are under development. This review gives an overview of novel strategies targeting the virus and/or the host cell for counteracting influenza virus infection.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24699705     DOI: 10.1007/s00018-014-1615-2

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  242 in total

1.  Structure-based identification of an inducer of the low-pH conformational change in the influenza virus hemagglutinin: irreversible inhibition of infectivity.

Authors:  L R Hoffman; I D Kuntz; J M White
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Redox regulation of the influenza hemagglutinin maturation process: a new cell-mediated strategy for anti-influenza therapy.

Authors:  Rossella Sgarbanti; Lucia Nencioni; Donatella Amatore; Paolo Coluccio; Alessandra Fraternale; Patrizio Sale; Caterina L Mammola; Guido Carpino; Eugenio Gaudio; Mauro Magnani; Maria R Ciriolo; Enrico Garaci; Anna Teresa Palamara
Journal:  Antioxid Redox Signal       Date:  2011-05-19       Impact factor: 8.401

Review 3.  Proteases essential for human influenza virus entry into cells and their inhibitors as potential therapeutic agents.

Authors:  Hiroshi Kido; Yuushi Okumura; Hiroshi Yamada; Trong Quang Le; Mihiro Yano
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

4.  Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus.

Authors:  Victoria Balannik; Jun Wang; Yuki Ohigashi; Xianghong Jing; Emma Magavern; Robert A Lamb; William F Degrado; Lawrence H Pinto
Journal:  Biochemistry       Date:  2009-12-22       Impact factor: 3.162

5.  Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication.

Authors:  Alexander Karlas; Nikolaus Machuy; Yujin Shin; Klaus-Peter Pleissner; Anita Artarini; Dagmar Heuer; Daniel Becker; Hany Khalil; Lesley A Ogilvie; Simone Hess; André P Mäurer; Elke Müller; Thorsten Wolff; Thomas Rudel; Thomas F Meyer
Journal:  Nature       Date:  2010-01-17       Impact factor: 49.962

6.  Proprotein-processing endoproteases PC6 and furin both activate hemagglutinin of virulent avian influenza viruses.

Authors:  T Horimoto; K Nakayama; S P Smeekens; Y Kawaoka
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

7.  Large-scale sequence analysis of M gene of influenza A viruses from different species: mechanisms for emergence and spread of amantadine resistance.

Authors:  Yuki Furuse; Akira Suzuki; Hitoshi Oshitani
Journal:  Antimicrob Agents Chemother       Date:  2009-08-03       Impact factor: 5.191

8.  Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N.

Authors:  Donald F Smee; Kevin W Bailey; Min-Hui Wong; Barry R O'Keefe; Kirk R Gustafson; Vasiliy P Mishin; Larisa V Gubareva
Journal:  Antiviral Res       Date:  2008-07-02       Impact factor: 5.970

9.  SUMOylation affects the interferon blocking activity of the influenza A nonstructural protein NS1 without affecting its stability or cellular localization.

Authors:  Andres Santos; Sangita Pal; Jason Chacón; Katherine Meraz; Jeanette Gonzalez; Karla Prieto; Germán Rosas-Acosta
Journal:  J Virol       Date:  2013-03-06       Impact factor: 5.103

10.  Inhibition of influenza infection by glutathione.

Authors:  Jiyang Cai; Yan Chen; Shaguna Seth; Satoru Furukawa; Richard W Compans; Dean P Jones
Journal:  Free Radic Biol Med       Date:  2003-04-01       Impact factor: 7.376

View more
  60 in total

1.  Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses.

Authors:  Yanmei Hu; Jiantao Zhang; Rami Ghassan Musharrafieh; Chunlong Ma; Raymond Hau; Jun Wang
Journal:  Antiviral Res       Date:  2017-08-02       Impact factor: 5.970

2.  An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses.

Authors:  Yanmei Hu; Rami Musharrafieh; Chunlong Ma; Jiantao Zhang; Donald F Smee; William F DeGrado; Jun Wang
Journal:  Antiviral Res       Date:  2017-01-10       Impact factor: 5.970

3.  Identification of NMS-873, an allosteric and specific p97 inhibitor, as a broad antiviral against both influenza A and B viruses.

Authors:  Jiantao Zhang; Yanmei Hu; Raymond Hau; Rami Musharrafieh; Chunlong Ma; Xu Zhou; Yin Chen; Jun Wang
Journal:  Eur J Pharm Sci       Date:  2019-03-28       Impact factor: 4.384

4.  The PA Endonuclease Inhibitor RO-7 Protects Mice from Lethal Challenge with Influenza A or B Viruses.

Authors:  Jeremy C Jones; Bindumadhav M Marathe; Peter Vogel; Rodolfo Gasser; Isabel Najera; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 5.  Re-understanding anti-influenza strategy: attach equal importance to antiviral and anti-inflammatory therapies.

Authors:  Zhengtu Li; Li Li; Shuai Zhao; Jing Li; Hongxia Zhou; Yunhui Zhang; Zifeng Yang; Bing Yuan
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

6.  Phenolic diterpenoid derivatives as anti-influenza a virus agents.

Authors:  Zhao Dang; Katherine Jung; Lei Zhu; Hua Xie; Kuo-Hsiung Lee; Chin-Ho Chen; Li Huang
Journal:  ACS Med Chem Lett       Date:  2015-01-29       Impact factor: 4.345

7.  Expeditious Lead Optimization of Isoxazole-Containing Influenza A Virus M2-S31N Inhibitors Using the Suzuki-Miyaura Cross-Coupling Reaction.

Authors:  Fang Li; Yanmei Hu; Yuanxiang Wang; Chunlong Ma; Jun Wang
Journal:  J Med Chem       Date:  2017-02-09       Impact factor: 7.446

8.  Identification and synthesis of quinolizidines with anti-influenza a virus activity.

Authors:  Zhao Dang; Katherine Jung; Lei Zhu; Weihong Lai; Hua Xie; Kuo-Hsiung Lee; Li Huang; Chin-Ho Chen
Journal:  ACS Med Chem Lett       Date:  2014-06-30       Impact factor: 4.345

9.  Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in vitro genetic barrier of drug resistance.

Authors:  Chunlong Ma; Fang Li; Rami Ghassan Musharrafieh; Jun Wang
Journal:  Antiviral Res       Date:  2016-07-28       Impact factor: 5.970

10.  Design and expeditious synthesis of organosilanes as potent antivirals targeting multidrug-resistant influenza A viruses.

Authors:  Yanmei Hu; Yuanxiang Wang; Fang Li; Chunlong Ma; Jun Wang
Journal:  Eur J Med Chem       Date:  2017-04-20       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.